GRDN Form 4 reports acquisition/exercise transactions

Morris David K reported acquisition or exercise transactions in a Form 4 filing for GRDN.

Rhea-AI Filing Summary

Morris David K reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.

Insights

Equity Compensation Analyst

Executive receives time-vested stock option grant, a standard long-term incentive.

Guardian Pharmacy Services granted Morris David K 50,000 stock options with a $34.59 exercise price, expiring on February 11, 2036. This is coded as an acquisition award, not an open-market purchase or sale, and is reported as directly owned.

The option vests in full on February 11, 2029, encouraging long-term alignment with the company’s performance. Because this is a single award with no immediate cash transaction or share issuance, its impact on existing shareholders appears routine based on the disclosed figures.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Morris David K

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full on February 11, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Guardian Pharmacy Services (GRDN) Form 4 report for Morris David K?

The Form 4 reports that Morris David K received a grant of 50,000 stock options to buy Class A Common Stock at an exercise price of $34.59 per share, awarded on February 11, 2026, as part of his executive and director compensation.

What are the key terms of Morris David K’s 50,000 stock options at GRDN?

The 50,000 stock options have an exercise price of $34.59 per share and relate to Class A Common Stock. They vest and become fully exercisable on February 11, 2029, and expire on February 11, 2036, providing long-dated equity incentives.

When do the Guardian Pharmacy (GRDN) options granted to Morris David K vest?

The options vest and become exercisable in full on February 11, 2029. Until that date, they function as an unexercisable award, designed to retain the executive and align his interests with the company’s long-term performance over several years.

How many derivative securities does Morris David K own in GRDN after this Form 4 transaction?

After the reported transaction, he beneficially owns 50,000 derivative securities in the form of stock options. These options, once vested and exercised, entitle him to purchase 50,000 shares of Guardian Pharmacy Services Class A Common Stock at $34.59 per share.

Is the Form 4 for Guardian Pharmacy (GRDN) a buy or sell of common stock?

The Form 4 reflects an award of stock options, coded as an acquisition, rather than a market buy or sell of existing shares. It is a compensation grant giving the right to purchase Class A Common Stock at $34.59 in the future, subject to vesting.

What positions does Morris David K hold at Guardian Pharmacy Services (GRDN)?

Morris David K is listed as both a director and an officer of Guardian Pharmacy Services. His officer role is specified as Executive Vice President and Chief Financial Officer, and this Form 4 documents equity compensation related to those leadership responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris David K

(Last) (First) (Middle)

300 GALLERIA PARKWAY SE, SUITE 800

(Street)

ATLANTA GA 30339

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardian Pharmacy Services, Inc. [ GRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.59	02/11/2026		A		50,000		(1)	02/11/2036	Class A Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full on February 11, 2029.

Remarks:

Executive Vice President and Chief Financial Officer

	/s/ Douglas Towns, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.